Michelle Mitchell: Long-Term Collaborative Research in Lung Cancer – Oncodaily

Michelle Mitchell, Chief Executive at Cancer Research UK (CRUK), shared a post on LinkedIn:
“One of the privileges of leading Cancer Research UK is seeing how long‑term, mission‑led funding can change how we understand cancer.
The TRACERx and PEACE studies are a powerful example of that. Together, they are helping researchers build a much clearer picture of how lung cancer (and other cancers) develop and change over time – from diagnosis through to the end of life.
This kind of insight doesn’t come from short‑term projects. It comes from sustained commitment, collaboration across disciplines, and the generosity of people who choose to take part in research so that others might benefit in the future.
Lydia was one of those people. After receiving a lung cancer diagnosis, she took part in both studies and went on to consent to post‑mortem research as part of PEACE. Thanks to her decision, researchers were able to learn more after her death in 2024, at the age of 87 – knowledge that will continue to shape research for years to come. Lydia, and many others like her, have left a lasting legacy.
This is why long‑term, collaborative research matters. And why Cancer Research UK remains committed to backing ambitious science that is driven by impact, partnership and people.
You can read more about the TRACERx and PEACE studies – and the impact of the latest results – here.”
Other articles about Lung Cancer on OncoDaily.
OncoDaily™ | © 2023 – 2025
All rights reserved. Unauthorized reproduction, distribution, or transmission of any content on OncoDaily.com is strictly prohibited. For permission requests or inquiries, please contact OncoDaily directly. By accessing and using OncoDaily.com, you acknowledge and agree to comply with this copyright notice, as well as our Privacy Policy, Editorial Policy, Cookie Policy, and Disclaimer. Continued use of this website constitutes acceptance of all such terms and policies.
Phone number: +1 978 717 48 84
Email: info@oncodaily.com

source